292 related articles for article (PubMed ID: 21199215)
1. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.
Martin JM; Danziger-Isakov LA
Pediatr Transplant; 2011 May; 15(3):229-36. PubMed ID: 21199215
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Management of cytomegalovirus infection and disease after solid-organ transplantation.
van der Bij W; Speich R
Clin Infect Dis; 2001 Jul; 33 Suppl 1():S32-7. PubMed ID: 11389520
[TBL] [Abstract][Full Text] [Related]
4. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
Puius YA; Snydman DR
Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
[TBL] [Abstract][Full Text] [Related]
6. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
[TBL] [Abstract][Full Text] [Related]
7. The case for cytomegalovirus prophylaxis in solid organ transplantation.
Snydman DR
Rev Med Virol; 2006; 16(5):289-95. PubMed ID: 16888821
[TBL] [Abstract][Full Text] [Related]
8. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
9. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
10. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
Griffiths P; Whitley R; Snydman DR; Singh N; Boeckh M;
Herpes; 2008 Oct; 15(1):4-12. PubMed ID: 18983762
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
12. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
[TBL] [Abstract][Full Text] [Related]
13. [Special considerations in the management of cytomegalovirus infection in pediatric solid organ transplant recipients].
Rumbao J; Frauca E
Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():70-3. PubMed ID: 22541928
[TBL] [Abstract][Full Text] [Related]
14. Management of CMV infection and disease in transplant patients. 27-29 February 2004.
Razonable RR; Emery VC;
Herpes; 2004 Dec; 11(3):77-86. PubMed ID: 15960905
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis against cytomegalovirus infection in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].
Ferrés M; Nervi B; Ramírez P
Rev Chilena Infectol; 2012 Sep; 29 Suppl 1():S23-8. PubMed ID: 23282552
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infections in transplant patients.
Ljungman P
Scand J Infect Dis Suppl; 1996; 100():59-63. PubMed ID: 8860355
[TBL] [Abstract][Full Text] [Related]
17. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
Kowalsky S; Arnon R; Posada R
Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
[TBL] [Abstract][Full Text] [Related]
18. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
19. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.
Suresh S; Lee BE; Robinson JL; Akinwumi MS; Preiksaitis JK
Pediatr Transplant; 2016 Nov; 20(7):970-980. PubMed ID: 27565955
[TBL] [Abstract][Full Text] [Related]
20. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
